Search research articles
Contact Us
Filters
Showing results (91-100 of 133) with videos related to
Page
of 14
Sort By:
ESMO Open
|
October 30, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis
F Salani, F R Ponziani, F Piscaglia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2012
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle
L Fornaro, F Crea, G Masi, et al.
Cancer Chemotherapy and Pharmacology
|
October 8, 2008
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
Lorenzo Fornaro, G Masi, S Bursi, et al.
British Journal of Cancer
|
May 25, 2013
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
F Loupakis, M Schirripa, C Caparello, et al.
Oncology
|
October 29, 2000
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study
M Lencioni, A Falcone, G Allegrini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2006
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
G Masi, L Marcucci, F Loupakis, et al.
British Journal of Cancer
|
March 17, 2011
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
F Loupakis, C Cremolini, A Fioravanti, et al.
British Journal of Cancer
|
March 26, 2008
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
G Allegrini, A Falcone, A Fioravanti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 20, 2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients
F Crea, L Fornaro, E Paolicchi, et al.
Journal of Mass Spectrometry : JMS
|
January 21, 2026
A Comprehensive Study of Anthocyanins in Two Fungal-Resistant Grape Varieties, Blueberry and Raspberry, by High-Resolution Mass Spectrometry
M De Rosso, K Muniyandi, K Kumar, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 133) with videos related to
Sort By:
Page
of 14
ESMO Open
|
October 30, 2025
Genomic profiling in hepatocellular carcinoma: a real-world retrospective analysis
F Salani, F R Ponziani, F Piscaglia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 3, 2012
EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle
L Fornaro, F Crea, G Masi, et al.
Cancer Chemotherapy and Pharmacology
|
October 8, 2008
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
Lorenzo Fornaro, G Masi, S Bursi, et al.
British Journal of Cancer
|
May 25, 2013
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
F Loupakis, M Schirripa, C Caparello, et al.
Oncology
|
October 29, 2000
Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study
M Lencioni, A Falcone, G Allegrini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 13, 2006
First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer
G Masi, L Marcucci, F Loupakis, et al.
British Journal of Cancer
|
March 17, 2011
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
F Loupakis, C Cremolini, A Fioravanti, et al.
British Journal of Cancer
|
March 26, 2008
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
G Allegrini, A Falcone, A Fioravanti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 20, 2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients
F Crea, L Fornaro, E Paolicchi, et al.
Journal of Mass Spectrometry : JMS
|
January 21, 2026
A Comprehensive Study of Anthocyanins in Two Fungal-Resistant Grape Varieties, Blueberry and Raspberry, by High-Resolution Mass Spectrometry
M De Rosso, K Muniyandi, K Kumar, et al.
Page
of 14